UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

European heart journal, 2021-09, Vol.42 (36), p.3727-3738

2021

Volltextzugriff (PDF)

The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics

European journal of heart failure, 2019-11, Vol.21 (11), p.1402-1411

2019

Volltextzugriff (PDF)

Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial

Circulation (New York, N.Y.), 2023-08, Vol.148 (5), p.381-390

2023

Volltextzugriff (PDF)

The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP)

American journal of kidney diseases, 2013-04, Vol.61 (4), p.S12-S23

2013

Volltextzugriff (PDF)

Diabetes status and other factors as correlates of risk for thrombotic and thromboembolic events during SARS-CoV-2 infection: A nationwide retrospective case–control study using Cerner Real-World Data

BMJ open, 2023-07, Vol.13 (7), p.e071475-e071475

2023

Volltextzugriff (PDF)

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

Circulation (New York, N.Y.), 2019-08, Vol.140 (7), p.e294-e324

2019

Volltextzugriff (PDF)

SGLT-2 Inhibitors in Heart Failure: Volume or Value?

Journal of the American College of Cardiology, 2021-03, Vol.77 (11), p.1393-1396

2021

Volltextzugriff (PDF)

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review

Heliyon, 2024-08, Vol.10 (16), p.e35916, Article e35916

2024

Volltextzugriff (PDF)

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

The Lancet (British edition), 2022-09, Vol.400 (10354), p.757-767

2022

Volltextzugriff (PDF)

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials

Journal of the American Heart Association, 2024-03, Vol.13 (5), p.e032279-e032279

2024

Volltextzugriff (PDF)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

ESC Heart Failure, 2021-08, Vol.8 (4), p.2603-2607

2021

Volltextzugriff (PDF)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Nature medicine, 2022-04, Vol.28 (4), p.809-813

2022

Volltextzugriff (PDF)

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial

Circulation (New York, N.Y.), 2021-04, Vol.143 (17), p.1673-1686

2021

Volltextzugriff (PDF)

Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure

The American journal of medicine, 2024-02, Vol.137 (2), p.S25-S34

2024

Volltextzugriff (PDF)

Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–ST‐Segment–Elevation Myocardial Infarction

Journal of the American Heart Association, 2018-06, Vol.7 (11), p.n/a

2018

Volltextzugriff (PDF)

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

The New England journal of medicine, 2023-09, Vol.389 (12), p.1069-1084

2023

Volltextzugriff (PDF)

Two Tales: One Story: EMPEROR-Reduced and DAPA-HF

Circulation (New York, N.Y.), 2020-12, Vol.142 (23), p.2201-2204

2020

Volltextzugriff (PDF)

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

The New England journal of medicine, 2021-01, Vol.384 (2), p.129-139

2021

Volltextzugriff (PDF)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

European heart journal, 2023-01, Vol.44 (1), p.41-50

2023

Volltextzugriff (PDF)

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

Circulation (New York, N.Y.), 2022-07, Vol.146 (4), p.279-288

2022

Volltextzugriff (PDF)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature medicine, 2021-11, Vol.27 (11), p.1954-1960

2021

Volltextzugriff (PDF)

Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility

Kidney international reports, 2022-09, Vol.7 (9), p.2059-2070

2022

Volltextzugriff (PDF)

Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF"

Circulation (New York, N.Y.), 2023-03, Vol.147 (11), p.922-923

2023

Volltextzugriff (PDF)

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

JAMA : the journal of the American Medical Association, 2020-04, Vol.323 (14), p.1353

2020

Volltextzugriff (PDF)

Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial"

Circulation (New York, N.Y.), 2024-09, Vol.150 (10), p.e226

2024

Volltextzugriff (PDF)

1 – 25 von 372

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(343)
Mit Volltextzugriff
(299)

Publikationsform

Artikel
(372)

Sprache

Englisch
(372)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(244)
Life Sciences & Biomedicine
(242)
Humans
(176)
Cardiac & Cardiovascular Systems
(161)
Cardiovascular System & Cardiology
(161)
Heart Failure
(135)
Male
(92)
Female
(86)
Aged
(83)
Diabetes
(78)
Heart Failure - Drug Therapy
(78)
Middle Aged
(74)
Diabetes Mellitus
(68)
Stroke Volume
(63)
Endocrinology & Metabolism
(52)
Diabetes Mellitus, Type 2 - Drug Therapy
(47)
Medicin Och Hälsovetenskap
(44)
Diabetes Mellitus, Type 2 - Complications
(38)
Benzhydryl Compounds - Therapeutic Use
(37)
Sodium-Glucose Transporter 2 Inhibitors - Therapeutic Use
(37)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Circulation
(63)
Jacc. Heart Failure
(42)
Journal Of The American College Of Cardiology
(40)
European Journal Of Heart Failure
(31)
Diabetes
(18)
Diabetes Care
(16)
Diabetes, Obesity & Metabolism
(16)
Jama Cardiology
(14)
Circulation. Heart Failure
(10)
The New England Journal Of Medicine
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(24)

Menü

Weitere Dienste

Einstellungen

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics

Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial

The Synergistic Relationship Between Estimated GFR and Microalbuminuria in Predicting Long-term Progression to ESRD or Death in Patients With Diabetes: Results From the Kidney Early Evaluation Program (KEEP)

Diabetes status and other factors as correlates of risk for thrombotic and thromboembolic events during SARS-CoV-2 infection: A nationwide retrospective case–control study using Cerner Real-World Data

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

SGLT-2 Inhibitors in Heart Failure: Volume or Value?

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial

Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure

Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–ST‐Segment–Elevation Myocardial Infarction

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Two Tales: One Story: EMPEROR-Reduced and DAPA-HF

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility

Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF"

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial"

Suchergebnisse filtern